Arrowhead Pharmaceuticals to Work with Janssen on Hepatitis B Treatment
October 04 2018 - 8:43AM
Dow Jones News
By Allison Prang
Arrowhead Pharmaceuticals Inc. (ARWR) and Janssen
Pharmaceuticals Inc. have agreed to work together on a treatment
for Hepatitis B, a deal that could provide Arrowhead with as much
as about $1.6 billion in payments.
The companies decided on a license and collaboration agreement
where they will work on the development and commercialization of a
treatment in Arrowhead's pipeline for treating Hepatitis B known as
ARO-HBV, Arrowhead said in a news release Thursday.
Janssen, part of the Janssen Pharmaceutical Companies of Johnson
& Johnson, gets the exclusive license for the treatment
program, Arrowhead said.
Arrowhead also said the two companies have agreed to possibly
work on as many as three more RNA interference therapeutics.
Arrowhead could get up to about $1.9 billion in payments related to
that work.
Arrowhead will be paid $175 million upfront, it said. The firm
will also get an equity investment of $75 million at $23 a share
from Johnson & Johnson Innovation, or JJDC Inc. Shares of
Arrowhead, up 404% year to date, rose 16% in premarket trading
Thursday.
Write to Allison Prang at allison.prang@wsj.com
(END) Dow Jones Newswires
October 04, 2018 08:28 ET (12:28 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024